MindWalk Holdings HYFT
NASDAQ HYFT
$1.31 -0.02 (-1.52%)
As of: Sep 4, 2026 · 12:56 PM EDT

MindWalk Holdings (HYFT) Non Operating Interest Expenses (2020 - 2026)

MindWalk Holdings (HYFT) posted quarterly Non Operating Interest Expenses of $241.81 for Q3 2022, down 99.82% year-over-year from $132679.2 in Q3 2021, and down 99.96% quarter-over-quarter from $583805.8 in Q2 2022.

Analysis

MindWalk Holdings (HYFT) Non Operating Interest Expenses (2020 - 2026) Analysis & Trends

MindWalk Holdings (HYFT) has reported Non Operating Interest Expenses for 3 consecutive years, with $241.81 the latest figure, recorded in Q3 2022.

  • In Q3 2022, Non Operating Interest Expenses fell 99.82% year-over-year to $241.81; the TTM figure through Jul 2022 stood at $584431.3 (down 8.98% YoY), while the FY2022 annual figure was $584270.8, up 10.59% from the prior year.
  • Non Operating Interest Expenses fell to $241.81 in Q3 2022 per HYFT's latest filing, from $583805.8 in the prior quarter.
  • Across five years, Non Operating Interest Expenses topped out at $583805.8 in Q2 2022 and bottomed at $180.14 in Q1 2022.
  • Historically, Non Operating Interest Expenses has averaged $138961.6 across 3 years, with a median of $132679.2 in 2021.
  • On a YoY basis, Non Operating Interest Expenses climbed as much as 449.75% in 2021 and fell as far as 99.89% in 2021.
  • MindWalk Holdings' Non Operating Interest Expenses stood at $193620.3 in 2020, then sank by 99.89% to $203.63 in 2021, then climbed by 18.75% to $241.81 in 2022.
  • Business Quant data shows HYFT's Non Operating Interest Expenses at $241.81 in Q3 2022, $583805.8 in Q2 2022, and $180.14 in Q1 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 139.31 Bn 131.46 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.65 Bn 77.66 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.94 Bn 52.80 Bn 52.00 Mn -
5 Revolution Medicines 44.05 Bn 44.05 Bn - 23.78 Mn
6 BeOne Medicines 39.96 Bn 34.86 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.16 Bn 31.85 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn - 93.62 Mn
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn 20.27 Mn
10 MindWalk Holdings 60.76 Mn 52.48 Mn 1.82 Mn -3,647.53
Historic Data

Historic Data

Download Data
DateValue
Apr 30, 2026 -3,647.53
Apr 30, 2025 -2,810.91
Jan 31, 2025 -2,113.28
Oct 31, 2024 -2,196.87
Apr 30, 2024 -2,950.08
Jan 31, 2024 -3,698.61
Oct 31, 2023 -3.69 Mn
Jul 31, 2023 -3,746.02
Apr 30, 2023 -19,954.33
Oct 31, 2022 -1.51 Mn
Jul 31, 2022 241,810.94
Apr 30, 2022 -532,160.16
Jan 31, 2022 180,138.61
Oct 31, 2021 203,632.07
Jul 31, 2021 132,679.23
Apr 30, 2021 147,891.85
Jan 31, 2021 167,821.63
Oct 31, 2020 128,429.27
Apr 30, 2020 3,540.01
Jan 31, 2020 105,934.24